Beneficial Effect of Consecutive Screening Mammography Examinations on Mortality from Breast Cancer: A Prospective Study




Duffy Stephen W, Tabár László, Yen Amy Ming-Fang, Dean Peter B, Smith Robert A, Jonsson Håkan, Törnberg Sven, Chiu Sherry Yueh-Hsia, Chen Sam Li-Sheng, Jen Grace Hsiao-Hsuan, Ku May Mei-Sheng, Hsu Chen-Yang, Ahlgren Johan, Maroni Roberta, Holmberg Lars, Chen Tony Hsiu-Hsi

PublisherRadiological Society of North America, Inc.

2021

Radiology

Radiology

Radiology

299

3

541

547

0033-8419

1527-1315

DOIhttps://doi.org/10.1148/radiol.2021203935

https://research.utu.fi/converis/portal/detail/Publication/59147597




Background

Previously, the risk of death from breast cancer was analyzed for women participating versus those not participating in the last screening examination before breast cancer diagnosis. Consecutive attendance patterns may further refine estimates.


Purpose

To estimate the effect of participation in successive mammographic screening examinations on breast cancer mortality.


Materials and Methods

Participation data for Swedish women eligible for screening mammography in nine counties from 1992 to 2016 were linked with data from registries and regional cancer centers for breast cancer diagnosis, cause, and date of death (Uppsala University ethics committee registration number: 2017/147). Incidence-based breast cancer mortality was calculated by whether the women had participated in the most recent screening examination prior to diagnosis only (intermittent participants), the penultimate screening examination only (lapsed participants), both examinations (serial participants), or neither examination (serial nonparticipants). Rates were analyzed with Poisson regression. We also analyzed incidence of breast cancers proving fatal within 10 years.


Results

Data were available for a total average population of 549 091 women (average age, 58.9 years ± 6.7 [standard deviation]). The numbers of participants in the four groups were as follows: serial participants, 392 135; intermittent participants, 41 746; lapsed participants, 30 945; and serial nonparticipants, 84 265. Serial participants had a 49% lower risk of breast cancer mortality (relative risk [RR], 0.51; 95% CI: 0.48, 0.55; P < .001) and a 50% lower risk of death from breast cancer within 10 years of diagnosis (RR, 0.50; 95% CI: 0.46, 0.55; P < .001) than serial nonparticipants. Lapsed and intermittent participants had a smaller reduction. Serial participants had significantly lower risk of both outcomes than lapsed or intermittent participants. Analyses correcting for potential biases made little difference to the results.


Conclusion

Women participating in the last two breast cancer screening examinations prior to breast cancer diagnosis had the largest reduction in breast cancer death. Missing either one of the last two examinations conferred a significantly higher risk.

Published under a CC BY 4.0 license.


Last updated on 2024-26-11 at 19:58